A team of investigators sought to investigate the usefulness of contrast-enhanced harmonic ultrasound-guided fine needle aspiration/biopsy when performed with no on-site cytopathology.
The American Cancer Society’s annual report approximates the new cancer diagnoses and deaths expected in 2021 and identifies impactful patterns in oncology care.
The ARC-8 study evaluated whether AB680, the anti-PD-1 antibody zimberelimab, and chemotherapy could improve metastatic pancreatic adenocarcinoma (PDAC) outcomes.
Preliminary data suggest that neoadjuvant treatment of resected pancreatic cancer with urelumab plus nivolumab and GVAX was well tolerated and showed some antitumor activity in a small study.
Risks of moving clinical trials online include missing key information about the patient experience — and higher dropout rates could also impair the overall quality of trials.
Durvalumab plus tremelimumab added to chemotherapy did not improve survival or response in metastatic pancreatic cancer, according to results of a phase 2 trial.
Using cohorts from 2 large observational studies, researchers investigated whether duration of diabetes and extent of weight loss may be a marker of risk for pancreatic cancer.
Zenocutuzumab is a first-in-class bispecific antibody that binds to HER2 and HER3 receptors, thereby blocking the interaction of HER3 with its ligand neuregulin 1 (NRG1) or NRG1-fusion proteins.
Neoadjuvant treatment with GEMCAP, FOLFIRINOX, or capecitabine plus radiotherapy prolonged OS compared with immediate surgery in patients with pancreatic cancer.
The study results suggest that patients with weight loss after age 50 years in the context of new-onset type 2 diabetes may be good candidates for pancreatic cancer screening.
